1
Tarran Jones
Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. MedImmune, Mueting Raasch & Gebhardt P A, March 4, 2014: US08664363

Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutation ...


2
Tarran Jones
LAROSA GREGORY J, HORVATH CHRISTOPHER, NEWMAN WALTER, JONES S TARRAN, O BRIEN SIOBHAN, O KEEFE THERESA: ANTICORPS HUMANISES ANTI-CCR2 ET PROCEDES DUTILISATION DE CES ANTICORPS, HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR. MILLENNIUM PHARMACEUTICALS, MILLENNIUM PHARMACEUTICALS, GOWLING LAFLEUR HENDERSON, May 21, 2013: CA2399080

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor (2) (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the inte ...


3
Tarran Jones
Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Aeres Biomedical, Jones Day, March 5, 2013: US08389688

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


4
Tarran Jones
Goldstein Neil I, Giorgio Nicholas A, Jones Steven Tarran, Saldanha Jose William: Antibody and antibody fragments for inhibiting the growth of tumors. Imclone Systems, April 1, 1998: EP0831880-A1

Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.


5
Winter Gregory Paul: Recombinant antibodies and methods for their production.. Winter Gregory Paul, September 30, 1987: EP0239400-A2 (917 worldwide citation)

An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity using recombinant DNA techniques. The gene coding sequences for producing the altered antibody may be produced ...


6
Padlan Eduardo A, Mark George E Iii, Daugherty Bruce L: A method for reducing the immunogenicity of antibody variable domains.. Merck & Co, Nat Inst Health, December 23, 1992: EP0519596-A1 (410 worldwide citation)

A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligand binding properti ...


7
Morrison Sherie L, Herzenberg Leonard A, Oi Vernon T: Chimeric receptors by dna splicing and expression.. Univ Leland Stanford Junior, March 5, 1986: EP0173494-A2 (394 worldwide citation)

Chimeric multi-subunit receptors are provided involving a binding region resulting from the organization of two subunit chains and a non-binding region which may have physiological significance. Particularly, chimeric immunoglobulins are provided having variable regions from one species and constant ...


8
Cabilly Shmuel, Holmes William Evans, Wetzel Ronald Burnell, Heyneker Herbert Louis, Riggs Arthur Dale: Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor.. Genentech, Hope City, November 14, 1984: EP0125023-A1 (379 worldwide citation)

Recombinant DNA techniques are used to produce both immunoglobulins which are analogous to those normally found in vertebrate systems and to take advantage of these gene modification techniques to construct chimeric or other modified forms.


9
Winter Gregory Paul, Gussow Detlef, Ward Elizabeth Sally: Cloning immunoglobulin variable domain sequences.. Medical Res Council, May 16, 1990: EP0368684-A1 (325 worldwide citation)

The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, met ...


10
Bosslet Klaus Dr, Hermentin Peter Dr, Seemann Gerhard Dr, Kuhlmann Ludwig Dr, Steinstraesser Axel Dr Dr: Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof.. Behringwerke, December 27, 1990: EP0404097-A2 (298 worldwide citation)

The invention relates to bispecific and oligospecific, mono- and oligovalent receptors which are prepared by genetic manipulation by fusion of DNA coding for F(ab) fragments of the antibodies of two or more different specificities, using suitable linkers. Preferably one of these specificities is dir ...